{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:43:47Z","timestamp":1783338227915,"version":"3.54.6"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"European Union, Interreg V \u00d6KS and Ferring Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>STUDY QUESTION<\/jats:title><jats:p>What are the downstream endocrine and paracrine consequences of letrozole (LZ) cotreatment during ovarian stimulation and is follicle growth and recruitment affected?<\/jats:p><\/jats:sec><jats:sec><jats:title>SUMMARY ANSWER<\/jats:title><jats:p>Letrozole cotreatment induces marked changes in both the follicular and luteal phase endocrinology causing potentiation of follicle diameter and an improved corpus luteum function without affecting the secondarily recruited follicle cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>WHAT IS KNOWN ALREADY<\/jats:title><jats:p>Letrozole is a third-generation aromatase inhibitor that is well-established as an effective ovulatory agent, while its possible benefits in standard in vitro fertilization protocols are less thoroughly investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title><jats:p>This study included a double-blinded, placebo-controlled, randomized study with LZ or placebo intervention during ovarian stimulation for IVF treatment, an observational preceding baseline natural cycle and a succeeding follow-up visit. Participants were enrolled between August 2016 and November 2018. Data from the randomized, stimulated cycle were part of a larger RCT, which was previously published.<\/jats:p><\/jats:sec><jats:sec><jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title><jats:p>The study was conducted at a public fertility clinic at Herlev Hospital, Denmark, including 31 healthy, normo-responding women eligible for IVF treatment. They underwent a natural baseline cycle and were subsequently randomized to receive either LZ 5\u2009mg (n\u2009=\u200916) or placebo (n\u2009=\u200915) daily during ovarian stimulation from cycle day (CD) 2\u20133 until induction of ovulation. Throughout both cycles, monitoring was performed every third day with transvaginal ultrasound for assessment of follicle count and diameter, and blood analyses for the determination of twelve endocrine and paracrine parameters. A follow-up assessment was performed at CD2\u20133 in the succeeding cycle. In the randomized part of the study, we determined differences in blood parameters, follicle recruitment, and follicle diameter. In the observational part of the study, we assessed follicle recruitment in between cycles and its correlation to endocrine parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title><jats:p>Letrozole cotreatment significantly suppressed oestradiol (E2) concentrations in the follicular phase (area under the curve (AUC) \u221258% (95% CI [\u221270%; \u221243%], P\u2009&amp;lt;\u20090.001)) and luteal phase (AUC \u221239% [\u221263%; \u22121%], P\u2009=\u20090.046). This had a marked effect on the endocrine and paracrine output with increased follicular phase luteinizing hormone (AUC +37% [3%; 82%], P\u2009=\u20090.033), androstenedione (AUC +36% [6%; 74%], P\u2009=\u20090.016), testosterone (AUC +37% [7%; 73%], P\u2009=\u20090.013) and 17-OH-progesterone (AUC +114% [10%; 318%], P\u2009=\u20090.027). Furthermore, follicle-stimulating hormone (FSH) was increased at stimulation day 5 in the LZ group (P\u2009&amp;lt;\u20090.05). In the luteal phase, increased corpus luteum output was reflected by elevated progesterone (AUC +44% [1%; 104%], P\u2009=\u20090.043), inhibin A (AUC +52% [11%; 108%], P\u2009=\u20090.011), androstenedione (AUC +31% [9%; 58%], P\u2009=\u20090.006) and testosterone (AUC +29% [6%; 57%], P\u2009=\u20090.012) in the LZ group. The altered balance between oestrogens and androgens was reflected in a markedly reduced SHBG concentration in the LZ group throughout the luteal phase (AUC \u221235% [\u221252%; \u221211%], P\u2009=\u20090.009). Endocrine and paracrine parameters were similar between groups at the follow-up visit. Letrozole cotreatment significantly increased the mean number of follicles &amp;gt;16\u2009mm at oocyte retrieval (7.2 vs 5.2, difference: 2.0, 95% CI [0.1; 3.8], P\u2009=\u20090.036), while the mean total number of follicles at oocyte retrieval was the same (23.7 vs 23.5, difference: 0.2 [\u22125.8; 6.1], P\u2009=\u20090.958), and the mean FSH consumption during the stimulated cycle was similar (1500 vs 1520\u2009IU, difference \u221220\u2009IU [\u2212175; 136], P\u2009=\u20090.794). Between cycles, the mean antral follicle count at CD2\u20133 was unchanged (natural cycle 19.0, stimulated cycle 20.9, follow-up cycle 19.7, P\u2009=\u20090.692) and there was no effect of LZ cotreatment on the recruitment of the next follicle cohort (test for interaction, P\u2009=\u20090.821).<\/jats:p><\/jats:sec><jats:sec><jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title><jats:p>This study included a relatively small, selected group of healthy women with an expected normal ovarian function and reserve, and the effects of LZ may therefore be different in other patient groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title><jats:p>We confirm some previous findings concerning increased follicle growth and increased endogenous FSH and androgen production, which support the rationale for further studies on the use of LZ cotreatment, for example, as a form of endogenous androgen priming sensitizing the follicle to FSH. Letrozole appears to improve the luteal phase with better stimulation of corpus luteum and progesterone secretion.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY FUNDING\/COMPETING INTEREST(s)<\/jats:title><jats:p>The authors declare no conflicts of interest relating to the present work.<\/jats:p><\/jats:sec><jats:sec><jats:title>TRIAL REGISTRATION NUMBER<\/jats:title><jats:p>NCT02939898.<\/jats:p><\/jats:sec>","DOI":"10.1093\/humrep\/deac119","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T07:29:29Z","timestamp":1654154969000},"page":"1557-1571","source":"Crossref","is-referenced-by-count":25,"title":["Effects of letrozole cotreatment on endocrinology and follicle development in women undergoing ovarian stimulation in an antagonist protocol"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1160-6924","authenticated-orcid":false,"given":"Liv C","family":"Poulsen","sequence":"first","affiliation":[{"name":"Department of Gynaecology and Obstetrics, Endocrinological and Reproductive Unit, Copenhagen University Hospital, Herlev Hospital , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka K","family":"Warzecha","sequence":"additional","affiliation":[{"name":"Department of Gynaecology and Obstetrics, Endocrinological and Reproductive Unit, Copenhagen University Hospital, Herlev Hospital , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie S","family":"B\u00fclow","sequence":"additional","affiliation":[{"name":"Department of Gynaecology and Obstetrics, Endocrinological and Reproductive Unit, Copenhagen University Hospital, Herlev Hospital , Herlev, Denmark"},{"name":"The Fertility Department, Copenhagen University Hospital , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bungum","sequence":"additional","affiliation":[{"name":"Fertility Clinic, Department of Gynaecology and Obstetrics, Zealand University Hospital , K\u00f8ge, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S","family":"Macklon","sequence":"additional","affiliation":[{"name":"Fertility Clinic, Department of Gynaecology and Obstetrics, Zealand University Hospital , K\u00f8ge, Denmark"},{"name":"London Women\u2019s Clinic , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Yding Andersen","sequence":"additional","affiliation":[{"name":"Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children and Reproduction, Copenhagen University Hospital , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven O","family":"Skouby","sequence":"additional","affiliation":[{"name":"Department of Gynaecology and Obstetrics, Endocrinological and Reproductive Unit, Copenhagen University Hospital, Herlev Hospital , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"2022070318361873700_deac119-B1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/molehr\/gaw070","article-title":"Inhibin-B secretion and FSH isoform distribution may play an integral part of follicular selection in the natural menstrual cycle","volume":"23","author":"Andersen","year":"2017","journal-title":"Mol Hum Reprod"},{"key":"2022070318361873700_deac119-B2","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1210\/jc.2006-1066","article-title":"Estradiol and regulation of anti-M\u00fcllerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles\u2019 fluid","volume":"91","author":"Andersen","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2022070318361873700_deac119-B3","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.fertnstert.2007.05.003","article-title":"Increased intrafollicular androgen levels affect human granulosa cell secretion of anti-M\u00fcllerian hormone and inhibin-B","volume":"89","author":"Andersen","year":"2008","journal-title":"Fertil Steril"},{"key":"2022070318361873700_deac119-B4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/humupd\/dmw025","article-title":"The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance","volume":"22","author":"Balen","year":"2016","journal-title":"Hum Reprod Update"},{"key":"2022070318361873700_deac119-B5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.rbmo.2021.12.006","article-title":"Co-treatment with letrozole during ovarian stimulation for IVF\/ICSI \u2013 a systematic review and meta-analysis","volume":"44","author":"B\u00fclow","journal-title":"Reprod Biomed Online"},{"key":"2022070318361873700_deac119-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humrep\/deab128.053","article-title":"Impact of letrozole co-treatment during ovarian stimulation with gonadotropins for in vitro fertilisation (IVF): a multicentre, randomised, double-blinded placebo-controlled trial","volume":"36","author":"B\u00fclow","year":"2021","journal-title":"Hum Reprod"},{"key":"2022070318361873700_deac119-B7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.fertnstert.2004.05.099","article-title":"Hormonal profile and endometrial morphology in letrozole-controlled ovarian hyperstimulation in ovulatory infertile patients","volume":"83","author":"Cort\u00ednez","year":"2005","journal-title":"Fertil Steril"},{"key":"2022070318361873700_deac119-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hropen\/hoac011","article-title":"Does adjuvant letrozole reduce uterine peristalsis prior to fresh embryo transfer?","volume":"2022","author":"Dreyer Holt","year":"2022","journal-title":"Hum Reprod Open"},{"key":"2022070318361873700_deac119-B9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.29252\/ijrm.15.2.101","article-title":"Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: an RCT","volume":"15","author":"Ebrahimi","year":"2017","journal-title":"Int J Reprod Biomed"},{"key":"2022070318361873700_deac119-B10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/09513590.2015.1110133","article-title":"Controlled ovarian hyperstimulation with sequential letrozole co-treatment in normo\/high responders","volume":"32","author":"Ecemis","year":"2016","journal-title":"Gynecol Endocrinol"},{"key":"2022070318361873700_deac119-B11","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S1701-2163(16)32551-8","article-title":"Fetal safety of letrozole and clomiphene citrate for ovulation induction","volume":"29","author":"Forman","year":"2007","journal-title":"J Obstet Gynaecol Canada"},{"key":"2022070318361873700_deac119-B12","first-page":"CD010287","article-title":"Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome","volume":"5","author":"Franik","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2022070318361873700_deac119-B13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.fertnstert.2005.01.117","article-title":"The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study","volume":"84","author":"Garcia-Velasco","year":"2005","journal-title":"Fertil Steril"},{"key":"2022070318361873700_deac119-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12958-017-0288-8","article-title":"Does daily co-administration of letrozole and gonadotropins during ovarian stimulation improve IVF outcome?","volume":"15","author":"Haas","year":"2017","journal-title":"Reprod Biol Endocrinol"},{"key":"2022070318361873700_deac119-B15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.fertnstert.2017.08.017","article-title":"In vitro fertilization treatments with the use of clomiphene citrate or letrozole","volume":"108","author":"Haas","year":"2017","journal-title":"Fertil Steril"},{"key":"2022070318361873700_deac119-B16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/oxfordjournals.humrep.a138480","article-title":"Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis","volume":"9","author":"Hillier","year":"1994","journal-title":"Hum Reprod"},{"key":"2022070318361873700_deac119-B17","doi-asserted-by":"crossref","DOI":"10.1016\/0303-7207(91)90234-J","article-title":"Effect of recombinant inhibin on androgen synthesis in cultured human thecal cells","volume":"75","author":"Hillier","year":"1991","journal-title":"Mol Cell Endocrinol"},{"key":"2022070318361873700_deac119-B18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1210\/jcem-72-6-1206","article-title":"Effect of recombinant activin on androgen synthesis in cultured human thecal cells","volume":"72","author":"Hillier","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2022070318361873700_deac119-B19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/molehr\/gat024","article-title":"Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection","volume":"19","author":"Jeppesen","year":"2013","journal-title":"Mol Hum Reprod"},{"key":"2022070318361873700_deac119-B20","article-title":"Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation","volume":"11","author":"Kamath","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2022070318361873700_deac119-B21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ogc.2004.08.008","article-title":"Hormonal regulation of implantation","volume":"31","author":"Kodaman","year":"2004","journal-title":"Obstet Gynecol Clin North Am"},{"key":"2022070318361873700_deac119-B22","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fendo.2017.00376","article-title":"Hallmarks of human small antral follicle development: implications for regulation of ovarian steroidogenesis and selection of the dominant follicle","volume":"8","author":"Kristensen","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2022070318361873700_deac119-B23","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1093\/humrep\/deq204","article-title":"Anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation and optimal timing of measurement for outcome prediction","volume":"25","author":"Lee","year":"2010","journal-title":"Hum Reprod"},{"key":"2022070318361873700_deac119-B24","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/humrep\/del221","article-title":"Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols","volume":"21","author":"Lossl","year":"2006","journal-title":"Hum Reprod"},{"key":"2022070318361873700_deac119-B25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3389\/fendo.2020.00627","article-title":"Biological and clinical rationale for androgen priming in ovarian stimulation","volume":"11","author":"L\u00f8ssl","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2022070318361873700_deac119-B26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1210\/er.2005-0015","article-title":"The science behind 25 years of ovarian stimulation for in vitro fertilization","volume":"27","author":"Macklon","year":"2006","journal-title":"Endocr Rev"},{"key":"2022070318361873700_deac119-B27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0015-0282(00)01705-2","article-title":"Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomifen citrate","volume":"75","author":"Mitwally","year":"2001","journal-title":"Fertil Steril"},{"key":"2022070318361873700_deac119-B28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7827-3-54","article-title":"The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of fertility treatment","volume":"3","author":"Mitwally","year":"2005","journal-title":"Reprod Biol Endocrinol"},{"key":"2022070318361873700_deac119-B29","first-page":"653","article-title":"N. Letrozole as co-treatment agent in ovarian stimulation antagonist protocol in poor responders: a double-blind randomized clinical trial","volume":"17","author":"Moini","year":"2019","journal-title":"Int J Reprod Biomed"},{"key":"2022070318361873700_deac119-B30","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1210\/jc.2006-0962","article-title":"Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy","volume":"91","author":"Oktay","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2022070318361873700_deac119-B31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.rbmo.2009.05.007","article-title":"Use of aromatase inhibitors in poor-responder patients receiving GnRH antagonist protocols","volume":"19","author":"\u00d6zmen","year":"2009","journal-title":"Reprod Biomed Online"},{"key":"2022070318361873700_deac119-B32","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0306-4530(02)00108-7","article-title":"Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change","volume":"28","author":"Pruessner","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"2022070318361873700_deac119-B33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","journal-title":"Fertil Steril"},{"key":"2022070318361873700_deac119-B34","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/000456329002700603","article-title":"Sex hormone binding globulin: origin, function and clinical significance","volume":"27","author":"Selby","year":"1990","journal-title":"Ann Clin Biochem"},{"issue":"Suppl 1","key":"2022070318361873700_deac119-B35","first-page":"S367","article-title":"Correlation between human follicular diameter and oocyte recovery, metaphase II oocytes and fertilization rate in intracytoplasmic sperm injection programs","volume":"84","author":"Sereepapong","year":"2001","journal-title":"J Med Assoc Thai"},{"key":"2022070318361873700_deac119-B36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13048-020-00666-z","article-title":"Does daily co administration of gonadotropins and letrozole during the ovarian stimulation improve IVF outcome for poor and sub optimal responders?","volume":"13","author":"Shapira","year":"2020","journal-title":"J Ovarian Res"},{"key":"2022070318361873700_deac119-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00018-020-03576-x","article-title":"New insights into anti-M\u00fcllerian hormone role in the hypothalamic\u2013pituitary\u2013gonadal axis and neuroendocrine development","volume":"78","author":"Silva","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"2022070318361873700_deac119-B38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/(SICI)1099-081X(199708)18:6<489::AID-BDD36>3.0.CO;2-P","article-title":"Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2\u00b75 mg single oral administration","volume":"18","author":"Sioufi","year":"1997","journal-title":"Biopharm Drug Dispos"},{"key":"2022070318361873700_deac119-B39","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"key":"2022070318361873700_deac119-B40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/cen.12186","article-title":"Endocrine effects of hCG supplementation to recombinant FSH throughout controlled ovarian stimulation for IVF: a dose-response study","volume":"79","author":"Thuesen","year":"2013","journal-title":"Clin Endocrinol"},{"key":"2022070318361873700_deac119-B41","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1472-6483(10)60611-6","article-title":"Aromatase inhibitors in ovarian stimulation for IVF\/ICSI: a pilot study","volume":"13","author":"Verpoest","year":"2006","journal-title":"Reprod Biomed Online"},{"key":"2022070318361873700_deac119-B42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.mce.2013.08.012","article-title":"Role of anti-M\u00fcllerian hormone and bone morphogenetic proteins in the regulation of FSH sensitivity","volume":"382","author":"Visser","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"2022070318361873700_deac119-B43","article-title":"Letrozole versus clomiphene citrate and natural cycle: endometrial receptivity during implantation window in women with polycystic ovary syndrome","volume":"11","author":"Wang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2022070318361873700_deac119-B44","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1210\/jcem.84.8.5929","article-title":"Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development","volume":"84","author":"Weil","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2022070318361873700_deac119-B45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/uog.18955","article-title":"Relationship between follicular volume and oocyte competence, blastocyst development and live-birth rate: optimal follicle size for oocyte retrieval","volume":"51","author":"Wirleitner","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2022070318361873700_deac119-B46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1472-6483(10)61826-3","article-title":"Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles","volume":"5","author":"Yding Andersen","year":"2002","journal-title":"Reprod Biomed Online"},{"key":"2022070318361873700_deac119-B47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12978-020-01042-2","article-title":"Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis","volume":"17","author":"Zhao","year":"2020","journal-title":"Reprod Health"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/7\/1557\/44386111\/deac119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/7\/1557\/44386111\/deac119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T15:13:48Z","timestamp":1700666028000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/37\/7\/1557\/6597083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,6,2]]},"published-print":{"date-parts":[[2022,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deac119","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,6,2]]}}}